Infliximab for vascular involvement in Behçet's syndrome

Gulen Hatemi, Nur Beyza Tukek,Sinem Nihal Esatoglu,Yesim Ozguler, Sitki Safa Taflan,Ugur Uygunoglu,Melike Melikoglu,Serdal Ugurlu,Izzet Fresko,Aksel Siva,Zekayi Kutlubay,Sebahattin Yurdakul,Hasan Yazici,Vedat Hamuryudan

Clinical Immunology（2023）

引用 1|浏览10

暂无评分

摘要

•Infliximab provided high remission and low relapse rates in vascular Behçet syndrome.•Infliximab is a favorable option for both remission induction and maintenance.•Pulmonary artery and venous involvement responded better than non-pulmonary arteries.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要